Author: Alex Strauss

  • |

    Teacher’s Diagnosis Highlights Mesothelioma Risk in Schools

    A recent mesothelioma diagnosis in the UK once again dramatically highlights the fact that even a small amount of asbestos can be deadly. Sixty-three-year-old school teacher Marion Potts of Brockenhurst died of mesothelioma in a Southampton hospital in June. According to an article in The Mirror, the Coroner recorded a verdict of “death from an industrial disease” after hearing evidence last week that Potts actually saw asbestos dust being released when she pinned work on the classroom walls. Most recently, Potts was head of the English department at Romsey School in Hampshire until her retirement two years ago. Mesothelioma is a growing threat among school teachers, administrators, maintenance workers, and even students in British schools. A government report released last…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    New Drugs May Be More Effective in Mesothelioma

    There is evidence that two novel mesothelioma medications may work better than some of the most commonly used drug treatments. Researchers in Stockholm, Sweden treated six mesothelioma cell lines with six different drugs, some of which are already commonly used to treat the asbestos-linked cancer.  The drugs tested include carboplatin, pemetrexed, doxorubicin and gemcitabine, all of which have been used to fight mesothelioma. The new drugs included in the tests were selenite (a form of selenium) and bortezomib (a proteasome inhibitor).  The researchers tested the drugs alone and in various combinations to see which were most effective. “As a single agent, selenite was effective on four out of six cell lines and, in combination with bortezomib, yielded the greatest response…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…

  • | |

    Mesothelioma Chemotherapy Could Get a Boost from Altered Virus

    An altered form of a virus that typically causes respiratory illness may help boost the effectiveness of chemotherapy for mesothelioma. In a study published in the Journal of Thoracic Oncology, researchers found that deleting a gene from adenoviruses made the drugs pemetrexed and cisplatin more cytotoxic to mesothelioma cells in the lab. In its unaltered state, the adenovirus is the virus most closely associated with respiratory problems, ranging from the common cold to pneumonia, croup and bronchitis.  It can also cause gastroenteritis, cystitis, and conjunctivitis. However, when it is altered in the lab by removing a particular gene, it can become a powerful ally in the fight against hard-to-treat cancers like mesothelioma. In the latest study, researchers first deleted the E1B-55kD…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Victims’ Victory in Pennsylvania

    Workers and their families have won a victory in Pennsylvania after the state Supreme Court ruled that they could sue former employers over late-manifesting industrial diseases like mesothelioma. The decision focused on a provision in Pennsylvania’s Workers’ Compensation Act that says workers cannot sue an employer if their occupational disease occurred more than 300 weeks after their on-the-job exposure. While many occupational injuries and diseases occur within weeks or months of exposure to a toxin, asbestos diseases like mesothelioma are a notable exception. Believed to be caused by chronic irritation from inhaled or ingested asbestos fibers, mesothelioma does not usually begin to cause symptoms until at least a decade after exposure. Expressing the opinion of the majority, Supreme Court Justice…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…